<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="879">
  <stage>Registered</stage>
  <submitdate>11/11/2005</submitdate>
  <approvaldate>11/11/2005</approvaldate>
  <actrnumber>ACTRN12605000727640</actrnumber>
  <trial_identification>
    <studytitle>Angiogenesis II-Safety and feasibility of autologous mesenchymal precursor cells (MPCs) in chronic myocardial ischaemia.</studytitle>
    <scientifictitle>Angiogenesis II-Safety and feasibility of autologous mesenchymal precursor cells (MPCs) in chronic myocardial ischaemia.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>End stage Ischaemic heart disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Left ventericular electromechanical mapping and adminsitration of MPCs</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective is to assess safety  of autologous MPCs in  the treatment of end stage ischaemic heart disease.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To demsontrate whether there is an improvement in quality of life, angina score, and a reduction in sublingual nitroglycerine tablet consumption and hospitisations.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Canadian Cardiologic Society (CCS) Angina Scale class III or IV.  Attempted best medical therapy including long acting nitrates, beta-blockers, and calcium channel blockers. Doses of each medication should be increased until haemodynamic consequences (bradycardia or hypotension) or intolerable drug-related side effects. Clinical signs and symptoms of significant ischaemia with reversible myocardial ischaemia on perfusion imaging. Subject must be able to complete a minimum of 3 minutes but no more than 10 minutes of Modified Bruce protocol. </inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unprotected left main coronary artery disease &gt;50%. Unstable angina pectoris (labile ECG changes) or a change in anti - anginal medication within the last three weeks. Myocardial infarction (Q wave or non-Q wave) and cerebrovascular events within the last three months. Left ventricular (LV) thrombus. Severe peripheral vascular disease precluding femoral artery access. Aortic stenosis that prohibited catheter access to the LV. De - compensated heart failure and/ or severe LV dysfunction (ejection fraction &lt;30%). Hypertrophic or restrictive cardiomyopathy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>2/11/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Mesoblast</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Mesoblast</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>John Hunter Hospital</ethicname>
      <ethicaddress>Newcastle</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tamara Lewis</name>
      <address>Mesoblast
Level 39
55 Collins Street
Melbourne VIC 3000</address>
      <phone>+61 3 96396036</phone>
      <fax>+61 3 96396030</fax>
      <email>tamara.lewis@mesoblast.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr Paul Rennie</name>
      <address>Mesoblast
Level 39
55 Collins Street
Melbourne VIC 3000</address>
      <phone>+61 3 96396036</phone>
      <fax>+61 3 96396030</fax>
      <email>paul.rennie@mesoblast.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>